Back
HCV Treatment 
Drug Advisories & Warnings
Drug Advisories & Warnings
FDA Warns Viekira Pak and Technivie for Hepatitis C Can Cause Serious Liver Injury
- Details
- Category: Drug Advisories & Warnings
- Published on Friday, 23 October 2015 00:00
- Written by FDA
The U.S. Food and Drug Administration (FDA) issued a warning this week that recently approved interferon-free therapy for hepatitis C virus (HCV) infection can produce serious liver damage, mainly in people who already have advanced liver disease. The warning applies to AbbVie's paritaprevir/ritonavir/ombitasvir coformulation, which is sold alone as Technivie for the treatment of HCV genotype 4, and as part of the Viekira Pak regimen for HCV genotype 1; in Europe the latter regimen is sold as separate components, Viekirax and Exviera.
More Articles...
- FDA Warns of Heart Risk When Combining Amiodarone with Sovaldi or Harvoni
- Complera Label Adds Low Viral Load Restriction, Liver Toxicity Warning
- Kaletra Label Updated to Add Drug Interactions, Including Boceprevir and Telaprevir
- Telaprevir Label Gets Black Box Warning about Serious Skin Rash
- Statin Interactions with HIV or Hepatitis C Drugs Can Cause Muscle and Kidney Damage, FDA Warns
- Pharmasset Halts Testing of HCV Polymerase Inhibitor PSI-938 Due to Liver Problems
- PegIntron Label Updated to Include Use with New Direct-Acting HCV Agents
- FDA Updates Dosing of Pegasys plus Ribavirin for Hepatitis C Patients with Kidney Impairment
- Updated PegIntron Label Psychiatric Warning
Web Design and Development by